Santen Pharmaceutical Co's market cap is currently ―. The company's EPS TTM is $0.486; its P/E ratio is ―; and it has a dividend yield of 2.31%. Santen Pharmaceutical Co is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is $0.17. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 70.87B	$ 63.38B	$ 65.53B	$ 70.46B	$ 67.04B
Gross Profit	$ 41.32B	$ 35.89B	$ 37.13B	$ 43.49B	$ 37.20B
EBIT	$ 8.63B	$ -27.77B	$ 9.20B	$ 10.42B	$ 7.57B
EBITDA	$ 12.76B	$ -23.22B	$ 13.67B	$ 14.93B	$ 11.81B
Net Income Common Stockholders	$ 5.98B	$ -28.71B	$ 6.66B	$ 7.87B	$ 5.04B
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 62.32B	$ 69.94B	$ 69.53B	$ 84.31B	$ 68.29B
Total Assets	$ 420.14B	$ 426.58B	$ 461.28B	$ 459.98B	$ 429.60B
Total Debt	$ ―	$ ―	$ ―	$ ―	$ ―
Net Debt	$ ―	$ ―	$ ―	$ ―	$ ―
Total Liabilities	-	-	-	-	-
Stockholders Equity	$ 300.93B	$ 310.07B	$ 343.56B	$ 337.49B	$ 321.40B
Cash Flow	-
Free Cash Flow	$ 5.41B	$ 6.24B	$ -3.83B	$ -473.00M	$ -1.92B
Operating Cash Flow	$ 10.15B	$ 15.91B	$ 2.42B	$ 14.86B	$ 4.09B
Investing Cash Flow	$ -4.79B	$ -12.59B	$ -6.23B	$ -11.93B	$ -6.18B
Financing Cash Flow	$ -11.87B	$ -2.35B	$ -13.77B	$ 9.71B	$ -7.12B

Currency in USD

Santen Pharmaceutical Co Earnings and Revenue History

Income Statement >

Santen Pharmaceutical Co Debt to Assets

Balance Sheet >

Santen Pharmaceutical Co Cash Flow

Cash Flow >

Santen Pharmaceutical Co Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing